Accueil   Diary - News   All news ORPHELIA PHARMA strengthens its capital base and accelerates its development

ORPHELIA PHARMA strengthens its capital base and accelerates its development




Paris, January 30, 2018 – ORPHELIA Pharma, a French biopharmaceutical dedicated to the development and marketing of pediatric drugs in the field of oncology and neurology today announces that it has strengthened its capital base in December 2017. The completion of this round of financing, subscribed exclusively by initiative OCTALFA, will allow the company to accelerate its projects with the ambitious objective to obtain three European marketing authorizations by the end of 2020.


« Our program for the three years to come is particularly rich with the opening of our pharmaceutical facility, the launch of three products, the recruitment of key employees and the strengthening of our academic and industrial research collaborations », comments Hugues Bienaymé, founder and General Manager of ORPHELIA Pharma. « Our activity is centered on the development of child-friendly formulations of essential drugs for the management of rare forms of epilepsy and for the treatment of the most aggressive forms of pediatric cancers for which the medical needs remain very high. Then, we will progressively add early-stage R&D projects, including the development of new molecules for these rare indications ».



Read the press release